Gilead Sciences (GILD)

Company ID: 222 | CIK: 0000882095
10-Q view:
No 10-K data
No 10-K data
No 10-K data
No 10-Q YTD data
No 10-Q 3M data
No 10-K data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q YTD data
No 10-Q 3M data
No 10-Q 3M data
Segments are charted by their disclosed metrics (revenue, segment profit, etc.). Each line is a single segment. Reconciliation/corporate items are excluded. Major customers are shown as a percentage of revenue. Operational KPIs are grouped by metric concept; sub-metrics appear as separate lines.

Geographic Segments

Business Unit / Product Segments

Major Customers (% of Revenue)

Operational KPIs

Remaining Roche milestone payments (backlog)

No 10-K data

Stockholders of Record (customers)

No 10-Q data

Employees (headcount)

No 10-Q data

Total inventories (inventory_units)

No 10-K data

Access program countries (other)

No 10-Q data

Accounts receivable - Southern Europe (other)

No 10-K data

Accounts receivable over 120 days past due (other)

No 10-K data

Accounts receivable past due (other)

No 10-K data

Accumulated deficit (other)

No 10-K data

Active Clinical Studies (other)

No 10-Q data

Active Phase 3 studies (other)

No 10-Q data

Active clinical studies (other)

No 10-Q data

Active product liability plaintiffs (other)

No 10-K data

Advertising and promotional expense (other)

No 10-Q data

Advertising expense (other)

No 10-Q data

Advertising expenses (other)

No 10-Q data

AmBisome Europe volume change (other)

No 10-K data

AmBisome full-year sales guidance (other)

No 10-K data

AmBisome sales growth (other)

No 10-K data

AmBisome sales guidance (other)

No 10-K data

AmBisome sales volume change (other)

No 10-K data

AmBisome share of net product sales (other)

No 10-K data

AmBisome share of product sales (other)

No 10-K data

AmBisome volume growth (other)

No 10-K data

Antiviral product sales growth (other)

No 10-K data

Antiviral sales force (other)

No 10-Q data

Approved marketed products (other)

No 10-Q data

Approved products marketed (other)

Atripla efavirenz component sales (other)

No 10-K data

Atripla share of antiviral sales (other)

No 10-K data

Auction rate securities (other)

No 10-K data

Auction rate securities fair value (other)

No 10-K data

Auction rate securities held (other)

No 10-Q data

Authorized share repurchase capacity (other)

No 10-K data

Authorized shares of common stock (other)

No 10-K data

Average repurchase price (other)

No 10-K data

Average share repurchase price (other)

No 10-K data

Basic and diluted net loss per common share (other)

No 10-K data

Cash and cash equivalents (other)

No 10-K data

Cash and investments (other)

No 10-K data

Cash and marketable securities (other)

No 10-K data

Cash and short-term investments (other)

No 10-K data

Cash cash equivalents and marketable securities (other)

No 10-K data

Cash used for share repurchases (other)

No 10-K data

Cash, cash equivalents and marketable debt securities (other)

No 10-K data

Cash, cash equivalents and marketable securities (other)

No 10-K data

Clinical-stage pipeline programs (other)

No 10-Q data

Clinical-stage programs (other)

No 10-Q data

Collaborations completed (other)

No 10-Q data

Common Shares Outstanding (other)

No 10-Q data

Common shares issued and outstanding (other)

No 10-K data

Common shares outstanding (other)

Common shares repurchased (other)

No 10-K data

Common shares used to calculate basic and diluted net loss per common share (other)

No 10-K data

Common stock repurchased (other)

No 10-K data

Contract research organization costs (other)

No 10-Q data

Convertible notes fair value (other)

No 10-K data

Cost of goods sold ratio (other)

No 10-K data

Countries of operation (other)

Countries where AmBisome sold (other)

No 10-Q data

Countries with AmBisome approval (other)

No 10-Q data

Countries with Complera/Eviplera (other)

No 10-Q data

Countries with DaunoXome approval (other)

No 10-Q data

Countries with Sovaldi available (other)

No 10-K data

Countries with Tamiflu sales (other)

No 10-Q data

Countries with VISTIDE approval (other)

No 10-Q data

Countries with marketing operations (other)

Countries with marketing subsidiaries (other)

No 10-Q data

Countries with operations (other)

Cumulative Biktarvy U.S. revenues (other)

No 10-K data

Debt-to-EBITDA ratio (other)

No 10-Q data

Descovy (FTC/TAF) product sales (other)

No 10-K data

Descovy-based share of product sales (other)

No 10-K data

Developing countries under generic licenses (other)

No 10-Q data

Dividend per share (other)

No 10-Q data

Dividends declared per share (other)

No 10-K data

Efavirenz inventory (other)

No 10-K data

Effective income tax rate (other)

Effective tax rate (other)

Equity in loss of unconsolidated affiliate (other)

No 10-K data

European receivables past due (other)

No 10-K data

FDA-approved products (other)

No 10-Q data

FX derivative notional (other)

No 10-K data

FX forward notional outstanding (other)

No 10-K data

FX hedge notional (other)

No 10-K data

FX hedge notional outstanding (other)

No 10-K data

FX impact on product sales (other)

No 10-K data

Female workforce percentage (other)

No 10-Q data

Female workforce share (other)

No 10-Q data

Foreign currency derivative notional (other)

No 10-K data

Foreign currency hedge notional (other)

No 10-K data

Foreign currency impact on product sales (other)

No 10-K data

Foreign currency notional outstanding (other)

No 10-K data

Foreign currency sales mix (other)

No 10-K data

Foreign currency sales share (other)

No 10-Q data

Foreign currency share of product sales (other)

No 10-K data

Generic partner manufacturers (other)

No 10-Q data

Gilead Access Program countries (other)

No 10-Q data

Government rebates (other)

No 10-Q data

Gross margin (other)

No 10-K data

Gross-to-net deductions (other)

No 10-Q data

HCV product sales (other)

No 10-K data

HCV sales share (other)

No 10-K data

HCV share of product sales (other)

HIV and other antiviral product sales (other)

No 10-K data

HIV prescription market share (other)

No 10-K data

HIV product sales (other)

No 10-K data

HIV product sales growth (other)

No 10-K data

HIV product sales guidance (other)

No 10-K data

HIV product volume growth (other)

HIV sales share (other)

No 10-K data

HIV share of product sales (other)

Hepatitis B antiviral prescription share (other)

No 10-K data

Hepsera sales guidance (other)

No 10-K data

Hepsera sales volume growth (other)

No 10-K data

Hepsera volume growth (other)

No 10-K data

Indefinite-lived intangible assets (other)

No 10-K data

International product sales mix (other)

No 10-K data

International product sales share (other)

No 10-Q data

International revenue mix (other)

No 10-K data

International sales mix (other)

No 10-K data

International sales share (other)

No 10-K data

International share of product sales (other)

No 10-Q data

Investment in unconsolidated affiliate (other)

No 10-K data

Marketable securities (other)

No 10-K data

Marketed products (other)

Marketing and sales staff (other)

No 10-Q data

Marketing subsidiaries (other)

No 10-Q data

Marketing subsidiary countries (other)

No 10-Q data

Milestone payments available (other)

No 10-K data

NRTI prescription share (other)

No 10-K data

Net cash provided by operating activities (other)

No 10-K data

Net loss (other)

No 10-K data

Non-U.S. product sales share (other)

No 10-K data

Non-retail channel share (other)

No 10-K data

Non-retail share of HIV business (other)

No 10-K data

Non-retail share of US HIV business (other)

No 10-K data

Nonvested stock options (other)

No 10-K data

Number of Reportable Segments (other)

Operating cash flow (other)

No 10-K data

Operating lease discount rate (other)

No 10-K data

Past due accounts receivable (other)

Performance shares granted (other)

No 10-K data

Phase 3 Clinical Trials (other)

No 10-Q data

Phase 3 clinical trials (other)

No 10-Q data

PrEP share on Descovy (other)

No 10-Q data

Pre-commercial Trodelvy inventory (other)

No 10-K data

Prescription market share (other)

No 10-K data

Product candidates in Phase III (other)

No 10-Q data

Product candidates in clinical trials (other)

No 10-Q data

Product gross margin (other)

Product sales (other)

No 10-K data

Product sales growth (other)

No 10-K data

Product sales in foreign currencies (other)

Product sales mix (other)

No 10-K data

Product sales outside U.S. (other)

Product sales outside US (other)

No 10-K data

Product sales outside United States (other)

No 10-K data

R&D full-year expense guidance (other)

No 10-K data

Ranexa prescription growth (other)

No 10-K data

Regional Directors (other)

No 10-Q data

Remaining buyback authorization (other)

No 10-K data

Remaining repurchase authorization (other)

No 10-K data

Remaining share repurchase authorization (other)

No 10-K data

Remdesivir doses donated (other)

No 10-K data

Remdesivir treatment courses (other)

No 10-K data

Remdesivir treatment courses available (other)

No 10-K data

Royalty revenue share (other)

No 10-Q data

SG&A full-year expense guidance (other)

No 10-K data

Sales Representatives (other)

No 10-Q data

Securities in unrealized loss (other)

No 10-K data

Series B preferred shares outstanding (other)

No 10-K data

Shares available for future grant (other)

No 10-K data

Shares available for grant (other)

No 10-K data

Shares of common stock outstanding (other)

No 10-K data

Shares outstanding (other)

Shares repurchased (other)

Shares reserved for equity plans (other)

No 10-Q data

Shares used in diluted EPS (other)

No 10-K data

Southern Europe accounts receivable (other)

No 10-K data

Southern Europe receivables past due (other)

No 10-K data

Stock options exercisable (other)

No 10-Q data

Stock options outstanding (other)

Stock repurchase program remaining (other)

No 10-K data

Stockholders of record (other)

No 10-Q data

TAF-based product sales (other)

No 10-K data

TDF-based product sales (other)

No 10-K data

Tamiflu royalty revenue (other)

No 10-K data

Third-party supplier evaluations initiated (other)

No 10-K data

Total assets (other)

No 10-K data

Total current assets (other)

No 10-K data

Total current liabilities (other)

No 10-K data

Total product sales growth (other)

No 10-K data

Total stockholders' equity (other)

No 10-K data

Truvada (FTC/TDF) share of product sales (other)

No 10-K data

Truvada share of HIV sales (other)

No 10-K data

Truvada share of antiviral sales (other)

No 10-K data

Truvada-based share of product sales (other)

No 10-K data

U.S. government rebates (other)

No 10-Q data

U.S. sales to top three wholesalers (other)

No 10-K data

U.S. wholesaler concentration (other)

No 10-K data

U.S. workforce composition (other)

No 10-Q data

US sales to top three wholesalers (other)

No 10-K data

Unrecognized stock-based compensation (other)

No 10-K data

Viread full-year sales guidance (other)

No 10-K data

Viread sales (other)

No 10-K data

Viread share of net product sales (other)

No 10-K data

Viread share of product sales (other)

No 10-K data

Warrants outstanding (other)

No 10-K data

Weighted average lease term (other)

No 10-K data

Wholesale channel concentration (other)

Wholesale customer concentration (other)

No 10-K data

Wholesaler channel concentration (other)

No 10-K data

Wholesaler channel inventory (other)

No 10-Q data

Wholesaler share of U.S. sales (other)

No 10-Q data

Women in leadership (other)

No 10-Q data

Women in leadership percentage (other)

No 10-Q data

Working capital (other)

No 10-K data

Y2K system upgrade completion (other)

No 10-K data

Year 2000 compliance costs (other)

No 10-K data

Year 2000 evaluation completion (other)

No 10-K data

Year 2000 upgrade completion (other)

No 10-K data

Patients on HIV medicines (patients)

Remdesivir treatment courses (production_volume)

No 10-K data

Buildings owned in Foster City (properties)

No 10-Q data

Leased Space (square_footage)

Patients on access program (users)

No 10-Q data
Human capital disclosures. Workforce totals and demographics are point-in-time. Flow metrics use the year-to-date period for 10-Q and full year for 10-K. Workforce actions (RIFs, restructurings, acquisition-related changes) are listed in the table at the bottom.

Workforce Totals

No 10-Q data
No 10-Q data

Demographics

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

Workforce Breakdowns

No 10-Q data
No 10-Q data
No 10-Q data
No 10-Q data

HCM Metrics — Point-in-Time

No point-in-time HCM metrics found.

HCM Metrics — Flow (Annual / YTD)

No flow HCM metrics found.

Workforce Actions

Period EndTypeStatusAffected% WorkforceAnnouncedExpected CompletionGeographySegment / FunctionChargeSourceNote
2026-06-30restructuringin_progressUSD 57 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended June 30, 2026 charges for severance from workforce reductions and facility exit costs ($17M in R&D, $40M in SG&A); no employee count or completion date disclosed. Remaining liability of $60M at 2026-06-30, majority expected to be paid within 12 months.
2026-06-30acquisition_additioncompleted2026-04United StatesOncologyUSD 7,000 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Arcellx, Inc. acquired for approximately $6.4B cash net of cash acquired; accounted for as an asset acquisition with $7.0B charged to acquired IPR&D. No headcount added disclosed; $375M stock-based compensation recorded for cash settlement of unvested employee awards.
2026-06-30acquisition_additioncompleted2026-05GermanyOncologyUSD 3,100 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tubulis GmbH acquired for approximately $3.2B cash net of cash acquired; asset acquisition with $3.1B charged to acquired IPR&D. No headcount added disclosed; $51M stock-based compensation for cash settlement of unvested employee awards.
2026-06-30acquisition_additioncompleted2026-06United StatesInflammationUSD 1,900 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ouro Medicines, LLC acquired for approximately $1.9B aggregate consideration ($1.6B cash net of cash acquired plus up to $500M contingent consideration, $277M fair value recorded); asset acquisition with $1.9B charged to acquired IPR&D, partially offset by $860M Lakefront payment. No headcount added disclosed; $135M stock-based compensation for cash settlement of unvested employee awards.
2026-06-30restructuringin_progressUSD 17 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to severance costs resulting from reductions in workforce and facility exit costs. Remaining liability of $60 million as of June 30, 2026.
2026-06-30restructuringin_progressUSD 57 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		YTD charges for six months ended June 30, 2026, primarily related to severance costs resulting from reductions in workforce and facility exit costs.
2026-06-30restructuringin_progressUSD 2,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressUSD 40 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2026 restructuring charges of $40M ($14M R&D, $25M SG&A) for severance from workforce reductions; $73M liability remaining at quarter-end, majority expected paid within 12 months. No employee count disclosed.
2026-03-31acquisition_additioncompleted2026-04-012026-04-30United StatesOncologyUSD 7,100 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Arcellx tender offer closed April 2026 for ~$7.1B cash; became wholly-owned subsidiary. No headcount added disclosed. Expected to be accounted for as an asset acquisition in Q2 2026.
2026-03-31acquisition_additionannounced2026-04-01GermanyOncologyUSD 3,200 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement April 2026 to acquire Tubulis GmbH for ~$3.2B upfront plus up to $1.9B contingent milestones; closing subject to regulatory clearances. No headcount disclosed.
2026-03-31acquisition_additionannounced2026-03-01United StatesInflammationUSD 1,700 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement March 2026 to acquire Ouro Medicines for ~$1.7B upfront plus up to $500M milestones; closing anticipated Q2 2026. Galapagos framework agreement shares 50% of upfront and milestones. No headcount disclosed.
2026-03-31restructuringin_progressUSD 40 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to severance costs resulting from reductions in workforce. Remaining liability of $73 million as of March 31, 2026.
2026-03-31restructuringin_progressResearch and Development Expense [Member]USD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 25,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2026-03-31restructuringin_progressUSD 40,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-12-31restructuringin_progressNot specifiedCompany-wide (charges recorded in Cost of goods sold, R&D and SG&A)USD 138 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		FY2025 restructuring charges primarily related to reductions in workforce; no employee count disclosed. Remaining liability of $61M at 2025-12-31, majority expected to be paid within 12 months. Prior-year charges (2024: $188M; 2023: $527M) excluded.
2025-12-31acquisition_additioncompleted2025-102025-10United StatesOncology — in vivo CAR therapeutics (Interius BioTherapeutics)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed October 2025 for approximately $350M cash; accounted for as an asset acquisition with a $311M charge to Acquired IPR&D. Headcount added not disclosed.
2025-12-31acquisition_additionannounced2026-02-222026-06-30United StatesOncology — BCMA CAR-T (Arcellx, Inc.)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Post-fiscal-year-end subsequent event: definitive merger agreement dated 2026-02-22; tender offer at $115/share plus $5/share CVR, estimated $7.0B excluding pre-existing holdings; closing anticipated in Q2 2026. Headcount added not disclosed.
2025-12-31restructuringcompletedUSD 138 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Charges primarily related to reductions in workforce. Total charges of $138 million recorded in 2025 ($4M COGS, $68M R&D, $66M SG&A). Remaining liability of $61 million as of year-end.
2025-12-31restructuringin_progressCost of Sales [Member]USD 4,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressResearch and Development Expense [Member]USD 68,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 66,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-12-31restructuringin_progressUSD 138,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2025-09-30restructuringin_progressNot specifiedResearch and development; Selling, general and administrativeUSD 101 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring charges primarily related to workforce reductions: $14M in Q3 2025 (R&D $8M, SG&A $5M) and $101M YTD 2025 (R&D $52M, SG&A $49M). Remaining liability of $52M at 2025-09-30, majority expected to be paid within 12 months. No employee counts or completion dates disclosed.
2025-09-30acquisition_additioncompletedUnited StatesOncology — in vivo CAR therapeuticsUSD 350 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closed October 2025 (after quarter end) acquisition of Interius BioTherapeutics for approximately $350M cash; Interius became a wholly-owned subsidiary. Headcount added not disclosed.
2025-09-30restructuringin_progressUSD 14 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to reductions in workforce. $8M in R&D and $5M in SG&A for the three months ended Sept 30, 2025.
2025-09-30restructuringin_progressUSD 101 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to reductions in workforce. $52M in R&D and $49M in SG&A for the nine months ended Sept 30, 2025. Remaining liability of $52M as of Sept 30, 2025.
2025-09-30restructuringin_progressResearch and Development Expense [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-09-30restructuringin_progressUSD 14,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressResearch and development; Selling, general and administrativeUSD 88 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Ongoing restructuring program driven mainly by workforce reductions; $88M charged in six months ended 2025-06-30 ($13M in Q2 2025: $6M R&D, $7M SG&A). Remaining liability of $92M at 2025-06-30, majority expected to be paid within 12 months. No employee counts, announcement date, or completion date disclosed.
2025-06-30restructuringin_progressUSD 13 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to reductions in workforce for the three months ended June 30, 2025. Employee count not disclosed.
2025-06-30restructuringin_progressUSD 88 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to reductions in workforce for the six months ended June 30, 2025. Employee count not disclosed.
2025-06-30restructuringin_progressResearch and Development Expense [Member]USD 6,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 7,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-06-30restructuringin_progressUSD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressUSD 74 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2025 restructuring charges of $74M, primarily workforce reductions; $38M in R&D and $36M in SG&A. $138M liability at 2025-03-31, majority expected paid within 12 months. Employee counts not disclosed.
2025-03-31restructuringin_progressUSD 74 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Incurred $74 million in restructuring charges primarily related to reductions in workforce. $38 million recorded in R&D and $36 million in SG&A. Liability of $138 million recorded as of March 31, 2025.
2025-03-31restructuringin_progressUSD 74,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressResearch and Development Expense [Member]USD 38,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2025-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 36,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-12-31restructuringin_progressNot specifiedCommercial and Research & Development workforceUSD 188 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2024 charges of $188M ($98M in R&D, $91M in SG&A) for reductions in commercial and R&D workforce; $93M liability recorded at year-end, majority expected to be paid within 12 months. Employee count not disclosed.
2024-12-31acquisition_additioncompleted2024-02-112024-03-31United StatesLiver Disease / Inflammation (seladelpar)USD 3,800 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of CymaBay Therapeutics completed March 2024 for $3.9B net of cash; $3.8B charged to acquired IPR&D expenses. Headcount added not disclosed.
2024-12-31restructuringcompleted2024Commercial and R&DUSD 188 (millions)restructuring_footnote
f5-10k / Qwen3.6-27B-Q8_0		Incurred $188 million in restructuring charges primarily related to the initiation of reductions in commercial and R&D workforce. Majority of liability expected to be paid in next 12 months.
2024-12-31restructuringin_progressUSD 188,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressResearch and Development Expense [Member]USD 98,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 91,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2024-09-30restructuringin_progressNot specifiedCommercial and Research & DevelopmentUSD 28 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q3 2024 charge of $28M ($112M YTD) for reductions in commercial and R&D workforce; $5M/$68M in R&D expense and $23M/$45M in SG&A for the three- and nine-month periods. No employee counts or completion dates disclosed.
2024-09-30restructuringin_progressCommercial and Research and DevelopmentUSD 28 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to initiation of reductions in commercial and R&D workforce for the three months ended Sept 30, 2024.
2024-09-30restructuringin_progressCommercial and Research and DevelopmentUSD 112 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges primarily related to initiation of reductions in commercial and R&D workforce for the nine months ended Sept 30, 2024.
2024-09-30restructuringin_progressUSD 28,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressResearch and Development Expense [Member]USD 5,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-09-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 23,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressNot specifiedCommercial and Research & DevelopmentUSD 84 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Six months ended June 30, 2024 charges of $84M ($63M in R&D, $22M in SG&A) from reductions in commercial and R&D workforce; three months portion was $21M ($13M R&D, $8M SG&A). No employee counts, announcement date, or completion timing disclosed.
2024-06-30acquisition_additioncompleted2024-03-012024-03-31United StatesLiver Disease / InflammationUSD 3,900 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CymaBay acquisition completed March 2024 for $3.9B net of cash; accounted for as asset acquisition. Headcount added not disclosed; $133M charge for cash settlement of unvested CymaBay employee stock awards.
2024-06-30restructuringin_progresscommercial and research and development workforceUSD 21 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred during the three months ended June 30, 2024, primarily related to the initiation of reductions in commercial and R&D workforce.
2024-06-30restructuringin_progresscommercial and research and development workforceUSD 84 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Charges incurred during the six months ended June 30, 2024, primarily related to the initiation of reductions in commercial and R&D workforce.
2024-06-30restructuringin_progressUSD 21,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressResearch and Development Expense [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-06-30restructuringin_progressSelling, General and Administrative Expenses [Member]USD 8,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressNot specifiedCommercial and Research & DevelopmentUSD 63 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Q1 2024 restructuring charges of $63M from reductions in commercial and R&D workforce; $50M in R&D expenses, $13M in SG&A. No employee count or completion date disclosed.
2024-03-31acquisition_additioncompleted2024-03-012024-03-31United StatesLiver Disease / Inflammation (seladelpar)USD 3,900 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CymaBay acquisition completed March 2024 for $3.9B net of cash; $3.9B charged to acquired IPR&D. Headcount added not disclosed; $133M share-based comp for cash settlement of unvested CymaBay employee stock awards.
2024-03-31restructuringin_progress2024-03-31Commercial and Research and DevelopmentUSD 63 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Initiation of reductions in commercial and R&D workforce. $50M recorded in R&D expenses, $13M in SG&A expenses. Employee count not disclosed.
2024-03-31restructuringin_progressUSD 63,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressResearch and Development Expense [Member]USD 50,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2024-03-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 13,000,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2023-12-31restructuringcompletedManufacturingUSD 527 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		2023 charges from changes in manufacturing strategy, including a decision to no longer utilize certain facilities: $381M manufacturing asset write-offs, $89M inventory write-offs, $57M other; split $479M COGS, $20M R&D, $28M SG&A. No employee count disclosed
2023-12-31acquisition_additioncompletedUnited StatesResearch and Developmentbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed February 2023; asset acquisition, ~$300M cash consideration. Headcount added not disclosed
2023-12-31acquisition_additioncompletedUnited StatesResearch and Developmentbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed May 2023; asset acquisition, ~$200M cash net of cash acquired. Headcount added not disclosed
2023-12-31acquisition_additionannounced2024-02United StatesResearch and Developmentsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement announced February 2024 to acquire CymaBay Therapeutics for ~$4.3B ($32.50/share tender offer); subsequent event after fiscal year-end. Headcount not disclosed
2023-12-31restructuringcompleted2023GlobalManufacturingUSD 479 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Restructuring expenses related to changes in manufacturing strategy, including write-offs of facilities, inventories, and other costs. Employee count not disclosed.
2023-12-31restructuringin_progressUSD 527,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressCost of Sales [Member]USD 479,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressResearch and Development Expense [Member]USD 20,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-12-31restructuringin_progressSelling, General and Administrative Expenses [Member]USD 28,000,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2023-09-30acquisition_additioncompleted2023-05United StatesOncology and immunology R&DUSD 170 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		XinThera acquisition closed May 2023 for ~$200M cash net of cash acquired; $170M charged to acquired IPR&D. Headcount added not disclosed.
2023-09-30acquisition_additioncompleted2023-02United StatesOncology (CAR T-cell therapy)USD 244 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Tmunity Therapeutics acquisition closed February 2023 for ~$300M cash; $244M charged to acquired IPR&D. Headcount added not disclosed.
2023-06-30acquisition_additioncompleted2023-05-01United StatesOncology and inflammation research (small molecule programs)USD 170 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closed May 2023 for ~$200M cash net of cash acquired; accounted for as an asset acquisition with $170M charged to acquired IPR&D. No employee headcount disclosed; up to ~$760M in contingent milestone payments to former shareholders.
2023-06-30acquisition_additioncompleted2023-02-01United StatesCell Therapy (next-generation CAR T-therapies)USD 244 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closed February 2023 for ~$300M cash for shares not already owned; asset acquisition with $244M charged to acquired IPR&D in Q1 2023. No employee headcount disclosed; up to ~$1.0B in potential future milestone and royalty payments.
2023-03-31acquisition_additioncompleted2023-02Cell TherapyUSD 244 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Closed February 2023; all outstanding Tmunity shares not already owned acquired for ~$300 million cash, making it a wholly-owned subsidiary. Tmunity is a clinical-stage developer of next-generation CAR T therapies. No employee headcount added was disclosed; the $244 million charge was recorded to Acquired in-process research and development expenses (asset acquisition accounting), with the remainder of purchase price allocated primarily to deferred tax assets. Former shareholders and the University of Pennsylvania are eligible for up to ~$1.0 billion in future milestone and royalty payments.
2022-12-31acquisition_additioncompleted2022-09-202022-09-20United KingdomInflammation / Research & DevelopmentUSD 414 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		All outstanding share capital acquired for $414 million cash; accounted for as an asset acquisition with a $389 million IPR&D charge. Headcount added not disclosed
2022-12-31acquisition_additioncompleted2022-122023-02United StatesOncology — Cell TherapyUSD 300 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement entered December 2022, closed February 2023 for approximately $300 million cash; brings preclinical and clinical CAR T programs. Headcount added not disclosed
2022-12-31othercompleted2022-122023-01United StatesOncology — Cell TherapyUSD 325 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Global strategic collaboration to co-develop and co-commercialize CART-ddBCMA; closed January 2023 with $225 million upfront cash and $100 million equity investment. Headcount impact not disclosed
2022-09-30plant_closurecompletedNew JerseyManufacturingMD&A
f5-10q / Qwen3.6-27B-Q8_0		Filing mentions 'restructuring costs for the closing of a New Jersey manufacturing site' included in Cost of Goods Sold. No specific headcount or charge amount is disclosed.
2022-06-30acquisition_additionannounced2022-08United KingdomResearch and DevelopmentUSD 405 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire MiroBio Ltd for $405M cash; expected to be accounted for as an asset acquisition. No headcount disclosed; closing subject to HSR antitrust clearance.
2022-03-31restructuringcompletedNew JerseyManufacturingMD&A
f5-10q / Qwen3.6-27B-Q8_0		Filing mentions 'restructuring costs for the closing of a New Jersey manufacturing site' impacting gross margin, but does not disclose employee counts or specific charge amounts.
2021-12-31acquisition_additioncompletedGermanyHBV/HDV (Hepcludex)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of MYR GmbH completed in the first quarter of 2021; MYR became a wholly-owned subsidiary and its results were consolidated from the acquisition date. Headcount added through the acquisition was not disclosed.
2021-09-30acquisition_additioncompleted2021-03-31GermanyHBV/HDV (Hepcludex)USD 1,561 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		MYR GmbH acquired in Q1 2021 for EUR 1.3 billion ($1.6 billion); MYR became a wholly-owned subsidiary and its results are consolidated from the acquisition date. No employee headcount added is disclosed in the filing.
2021-03-31acquisition_additioncompleted2021-03-04GermanyR&D / Commercializationbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Completed acquisition of MYR GmbH on March 4, 2021. MD&A notes 'headcount growth due to the fourth quarter 2020 acquisition of Immunomedics' and implies growth from MYR, but no specific employee count is disclosed for MYR in this filing.
2021-03-31acquisition_additioncompleted2020-10-23GlobalOncology / Cell TherapyMD&A
f5-10q / Qwen3.6-27B-Q8_0		MD&A attributes higher R&D expenses in Q1 2021 to 'headcount growth due to the fourth quarter 2020 acquisition of Immunomedics'. No specific headcount number is provided in this 10-Q.
2020-12-31acquisition_additioncompleted2020-04-072020-04-07United StatesOncology (R&D)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired all outstanding Forty Seven stock for $4.7 billion total consideration, net of acquired cash; accounted for as an asset acquisition. No headcount added disclosed.
2020-12-31acquisition_additioncompleted2020-10-232020-10-23United StatesOncology (commercial and R&D)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Cash consideration of $20.6 billion; accounted for as a business combination. Immunomedics excluded from management's and the auditor's ICFR assessment (3% of total assets, 11% of total liabilities, under 1% of 2020 revenues). No headcount added disclosed.
2020-12-31acquisition_additionannounced2020-12-102021-03-31GermanyViral hepatitisbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement to acquire MYR for approximately EUR 1.2 billion cash plus up to EUR 300 million contingent on FDA approval of Hepcludex; expected to close by end of Q1 2021, subject to regulatory clearances. No headcount disclosed.
2020-06-30acquisition_additioncompleted2020-04-072020-04-07United StatesOncology (R&D and corporate)USD 4,500 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquired IPR&D charge of $4.5B for magrolimab; no employee headcount added disclosed. Also recorded $144M share-based comp for cash settlement of unvested Forty Seven awards.
2020-06-30acquisition_additionannounced2020-05-272020-07-13United StatesOncologyUSD 175 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Collaboration closed 2020-07-13 with $175M upfront and $200M equity purchase; Gilead holds ~13% of Arcus. No headcount disclosed.
2020-06-30acquisition_additionannounced2020-06-192020-07-13United StatesOncology (immuno-oncology)USD 275 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		49.9% equity interest acquired for $275M cash, closed 2020-07-13; option to acquire remainder for $315M plus up to $1.2B milestones. No headcount disclosed.
2020-06-30acquisition_additionannounced2020-07-172020-09-30United StatesOncology (cancer immunotherapy)USD 300 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent event: 49.9% interest for $300M cash; option for remainder up to $1.3B. Expected to close Q3 2020. No headcount disclosed.
2020-03-31acquisition_additioncompleted2020-03-012020-04-07United StatesResearch and Development (Immuno-oncology)USD 4,900 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Forty Seven, Inc. for approximately $4.9 billion ($95.50/share cash), closed April 7, 2020. Treated as asset acquisition; purchase price expensed as IPR&D in Q2 2020. No employee headcount disclosed.
2017-12-31acquisition_additioncompleted2017-10-032017-10-03United StatesHematology/Oncology — cell therapybusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tender offer completed at $180 per share, total consideration $11,155 million; Kite became a wholly-owned subsidiary. Filing does not disclose Kite employee headcount added.
2017-12-31acquisition_additioncompleted2017-122017-12United StatesCell therapy research and developmentbusiness_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquired all outstanding stock in December 2017 (exact day not disclosed); cash consideration $150 million net of acquired cash, plus up to $322 million contingent milestones. Employee headcount added not disclosed.
2017-12-31acquisition_additioncompleted2017-10-032017-10-03GlobalHematology/OncologyItem 1_Business
f5-10k / Qwen3.6-27B-Q8_0		Acquired Kite Pharma, Inc. in October 2017. Specific headcount added not disclosed in this filing.
2017-12-31acquisition_additioncompleted2017-12-312017-12-31GlobalCellular TherapyItem 1_Business
f5-10k / Qwen3.6-27B-Q8_0		Acquired Cell Design Labs, Inc. in December 2017. Specific headcount added not disclosed in this filing.
2016-12-31acquisition_additioncompleted2016-05-01United StatesResearch and DevelopmentUSD 400 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		May 2016 acquisition of Nimbus Apollo, Inc. and its ACC inhibitor program; accounted for as an asset acquisition with $400M expensed to R&D plus up to $800M contingent milestones. Headcount added not disclosed.
2013-12-31acquisition_additioncompleted2013-02-082013-02-08CanadaResearch and DevelopmentUSD 488 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of YM BioSciences completed February 8, 2013 for total consideration of $487.6 million; headcount added not disclosed. Charge shown is total consideration, not a severance charge.
2013-06-30acquisition_additioncompleted2013-02-08Research and Development (oncology/hematologic cancers)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of YM BioSciences completed 2013-02-08 for $487.6 million total consideration; no employee headcount added or retained was disclosed in the filing.
2012-12-31acquisition_additioncompleted2011-11-212012-01-17United StatesResearch and Development (HCV)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		$11.05 billion cash acquisition of Pharmasset completed January 2012; headcount added not disclosed. Related restructuring costs of $15.1 million were incurred in 2012 (see separate record).
2012-12-31restructuringcompletedUnited StatesPharmasset acquisition integrationUSD 15 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Restructuring costs of $15.1 million recorded in 2012 in connection with the Pharmasset acquisition; employees affected and completion timeline not disclosed.
2012-12-31acquisition_additioncompleted2013-02-08CanadaOncology/InflammationUSD 490 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive agreement signed in December 2012 for approximately $490 million; transaction completed February 8, 2013, after fiscal year-end. Headcount added not disclosed; announcement date stated only as December 2012.
2012-12-31restructuringcompleted2012USD 15 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Restructuring costs of $15.1 million incurred in connection with the acquisition of Pharmasset. Employee count not disclosed.
2012-12-31restructuringin_progressUSD 15,125,000 (absolute)restructuring_footnote
f5-10k / no-ai-xblr
2012-09-30restructuringin_progressUSD 15 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring costs of $14.9M incurred in nine months ended 2012-09-30 related to Pharmasset acquisition; no employee counts, dates, or geography disclosed.
2012-09-30acquisition_additioncompleted2012-01-172012-01-17United StatesResearch & Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Pharmasset acquisition closed 2012-01-17; headcount added not disclosed. $193.9M stock-based comp from accelerated option vesting recorded.
2012-09-30restructuringin_progressUSD 14,929,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-06-30acquisition_additioncompleted2012-01-17United StatesResearch and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Completed acquisition of Pharmasset for $11.1 billion cash; no employee headcount added disclosed. Merger agreement entered in November 2011; results consolidated from January 13, 2012.
2012-06-30restructuringin_progressUSD 12 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring costs of $11,512 thousand incurred in connection with the Pharmasset acquisition during the six months ended June 30, 2012; no employee counts, timing, or geography disclosed.
2012-06-30acquisition_additioncompleted2012-01-17USD 193,937 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition completed Jan 17, 2012. Headcount not disclosed. $193.9M stock-based compensation expense recognized for accelerated vesting of employee options.
2012-06-30restructuringcompleted2012-01-17USD 11,512 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring costs of $11.5M incurred in connection with the Pharmasset acquisition during the six months ended June 30, 2012. Employee count not disclosed.
2012-06-30restructuringin_progressUSD 11,512,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2012-03-31acquisition_additioncompleted2011-112012-01-17United StatesResearch and developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger agreement entered into in November 2011 (exact day not disclosed); acquisition completed January 17, 2012 for $11.1 billion cash. Pharmasset was integrated into Gilead's operations during Q1 2012. No employee headcount added through the acquisition is disclosed.
2012-03-31restructuringin_progressUSD 8 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring costs of $8.3 million recognized in Q1 2012 as an 'other cost' of the Pharmasset acquisition (also referenced in MD&A). The filing does not disclose affected employee counts, geography, function, announcement date or completion timing.
2012-03-31acquisition_additioncompleted2012-01-17USD 11,052,309 (units)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition completed Jan 17, 2012. Total cash paid $11.1 billion. Headcount added not explicitly disclosed. MD&A notes 'impact of higher headcount' and 'expenses associated with acquisitions'.
2012-03-31restructuringcompleted2012-03-31USD 8,343 (thousands)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Restructuring costs of $8.3 million incurred in Q1 2012 related to the Pharmasset acquisition. Employee count affected not disclosed.
2012-03-31restructuringin_progressUSD 8,343,000 (absolute)restructuring_footnote
f5-10q / no-ai-xblr
2011-12-31restructuringin_progress2009-06-30United StatesCardiovascular operations (R&D re-alignment and facilities exit)USD 7 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Program approved in Q2 2009 (announcement date approximated to quarter-end) to capture CV Therapeutics acquisition synergies. Only FY2011 activity extracted: $6.7M of facilities-related expense recorded in SG&A during 2011. Cumulative program totals of $43.5M (SG&A) and $29.1M (R&D) are multi-year and not FY2011 figures. No employees-affected count disclosed; no further significant costs expected.
2011-12-31acquisition_additioncompleted2010-12-192011-01-14United States (Palo Alto, California)Research and Development (fibrotic diseases and cancer)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement dated December 19, 2010; closed January 14, 2011. Total consideration transferred of $227.1M. Headcount added through the acquisition is not disclosed.
2011-12-31acquisition_additioncompleted2011-02-212011-04-01United States (Seattle, Washington)Research and Development (cancer and inflammatory diseases)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger agreement dated February 21, 2011; closed April 1, 2011. Total consideration transferred of $484.3M. Headcount added through the acquisition is not disclosed.
2011-12-31acquisition_additioncompleted2011-11-212012-01-17United States (Princeton, New Jersey)Research and Development (hepatitis C virus)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Subsequent event relative to FY2011: merger agreement dated November 21, 2011, transaction closed January 17, 2012 for $11.1 billion, financed with approximately $5.2B cash on hand, $2.2B bank debt and $3.7B senior unsecured notes. Headcount added is not disclosed; purchase price allocation was still in process at filing.
2011-12-31restructuringcompleted2010-06-302010-12-31North Carolina, USAResearch and DevelopmentUSD 25 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan to close research operations in Durham, NC and consolidate liver disease research in Foster City, CA. Operations closed in Dec 2010. Total charges $14.6M SG&A and $10.4M R&D.
2011-12-31restructuringcompleted2009-06-302011-12-31GlobalCardiovascular OperationsUSD 73 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan to realize synergies from CV Therapeutics acquisition. Total costs incurred $43.5M SG&A and $29.1M R&D. No additional significant costs expected.
2011-09-30acquisition_additioncompleted2010-12-012011-01-14United States (Palo Alto, California)Research and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed January 14, 2011; no employee headcount added disclosed. Consideration $227.1 million.
2011-09-30acquisition_additioncompleted2011-02-012011-04-01United States (Seattle, Washington)Research and Development (Oncology and Inflammation)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed April 1, 2011; no employee headcount added disclosed. Consideration $484.3 million.
2011-06-30acquisition_additioncompleted2010-12-012011-01-14United States (Palo Alto, California)Research and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed January 14, 2011; no employee headcount added disclosed in the filing.
2011-06-30acquisition_additioncompleted2011-02-012011-04-01United States (Seattle, Washington)Research and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed April 1, 2011; no employee headcount added disclosed in the filing.
2011-06-30acquisition_additioncompleted2010-12-012011-01-14Palo Alto, CaliforniaResearch and Developmentbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition closed Jan 14, 2011. Filing notes 'higher headcount' in MD&A but does not disclose specific employee count added.
2011-06-30acquisition_additioncompleted2011-02-012011-04-01Seattle, WashingtonResearch and Developmentbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition closed Apr 1, 2011. Filing notes 'higher headcount' in MD&A but does not disclose specific employee count added.
2011-03-31acquisition_additioncompleted2010-122011-01-14United StatesResearch and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Development-stage biotech acquired for $225 million plus contingent sales-based payments; closed 2011-01-14. No employee count disclosed; purchase accounting preliminary at quarter-end.
2011-03-31acquisition_additioncompleted2011-02-212011-04-01United StatesResearch and Developmentsubsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger agreement dated 2011-02-21; $375 million up-front plus up to $225 million in milestones; closed 2011-04-01, after quarter-end. No employee count disclosed; purchase price allocation not yet performed.
2011-03-31acquisition_additioncompleted2010-12-012011-01-14Palo Alto, CaliforniaResearch and DevelopmentUSD 225 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition closed Jan 14, 2011. Headcount not disclosed. Consideration $225M plus potential future payments.
2011-03-31acquisition_additionannounced2011-02-012011-04-01Seattle, WashingtonResearch and DevelopmentUSD 375 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Transaction closed April 1, 2011. Headcount not disclosed. Consideration $375M plus up to $225M milestones.
2010-12-31plant_closurecompleted2010-06-302010-12-31United States — Durham, North CarolinaResearch and Development (liver disease research)USD 25 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approved in Q2 2010; $14.6M in SG&A and $10.4M in R&D recorded in 2010. Operations closed December 2010; no additional significant costs expected. Headcount affected not disclosed.
2010-12-31restructuringcompleted2009-06-302010-12-31United StatesCardiovascular operations (CV Therapeutics integration)USD 14 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program approved Q2 2009; only current-year 2010 activity captured ($10.6M SG&A + $3.4M R&D). Program totals to date: $36.8M SG&A and $29.1M R&D. No further costs expected.
2010-12-31acquisition_additioncompleted2010-06-232010-07-08United States — Branford, ConnecticutResearch and Development (small molecule / kinase biology)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed July 8, 2010 for up to $120.0M ($91.0M upfront plus up to $29.0M contingent). Headcount added not disclosed.
2010-12-31acquisition_additioncompleted2010-12-192011-01-14United States — Palo Alto, CaliforniaResearch and Development (fibrotic diseases and cancer)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Closed January 14, 2011 for $225 million plus potential future sales-based payments. Purchase accounting still in process at filing date; headcount added not disclosed.
2010-12-31acquisition_additionannounced2011-02-282011-06-30United States — Seattle, WashingtonResearch and Development (oncology and inflammatory diseases)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Agreement to acquire Calistoga Pharmaceuticals for $375 million plus up to $225 million in milestones; expected to close Q2 2011. Headcount not disclosed.
2010-12-31restructuringcompleted2010-06-302010-12-31Durham, North CarolinaResearch and DevelopmentUSD 25 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan to close research operations in Durham, NC and consolidate liver disease research in Foster City, CA. Total expenses of $25.0 million incurred in 2010 for employee severance and facilities-related expenses. Operations closed in December 2010.
2010-12-31restructuringcompleted2009-06-302010-12-31United StatesCardiovascular OperationsUSD 14 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in Q2 2009 to realize synergies from CV Therapeutics acquisition. In 2010, recorded $10.6 million in SG&A and $3.4 million in R&D ($14.0 million total) for employee severance, relocation, lease termination, and facilities costs. No additional costs expected.
2010-09-30restructuringin_progress2009-04-01United StatesCardiovascular R&D and operationsUSD 16 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CV Therapeutics synergy plan approved Q2 2009; nine-month 2010 charges of $13.2M SG&A and $3.2M R&D. Cumulative $39.4M SG&A and $28.9M R&D to date. No employee count disclosed.
2010-09-30plant_closurein_progress2010-04-012010-12-31United StatesLiver disease R&DUSD 8 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan to close Durham, NC operations and consolidate liver disease work in Foster City, CA. Nine-month 2010 charges of $1.4M SG&A and $7.0M R&D. Additional $13.5M expected in Q4 2010; total program ~$21.9M. No employee count disclosed.
2010-09-30acquisition_additioncompleted2010-06-012010-07-08United StatesResearch & Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of CGI Pharmaceuticals closed July 8, 2010 for $102.1M total consideration. No headcount figure disclosed for acquired employees.
2010-09-30restructuringin_progress2010-04-012010-12-31Durham, North CarolinaLiver Disease R&DUSD 22 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan to close Durham operations and consolidate liver disease work in Foster City. Total expected cost approx $21.9M ($11.6M severance, $10.3M facilities). Employee count not disclosed.
2010-09-30restructuringin_progress2009-04-012010-12-31United StatesCardiovascular R&D and OperationsUSD 69 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Synergy plan following CV Therapeutics acquisition. Total expected cost approx $68.7M ($36.3M severance/relocation, $32.4M facilities). Employee count not disclosed.
2010-09-30acquisition_additioncompleted2010-06-012010-07-08Branford, ConnecticutR&Dbusiness_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of CGI Pharmaceuticals closed July 8, 2010. Headcount added not explicitly disclosed.
2010-06-30plant_closurein_progress2010-06-302010-12-31United States (Durham, North Carolina)Liver disease R&D; operationsUSD 24 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in Q2 2010 to close Durham operations and consolidate liver disease work in Foster City, CA; total expected charge comprises ~$12.3M severance/termination benefits and ~$12.0M facilities-related expenses; $22.6M expected in H2 2010. No employee count disclosed. Announcement date reflects quarter of approval; specific date not stated.
2010-06-30restructuringin_progress2009-06-30United StatesCardiovascular R&D and operations (CV Therapeutics integration)USD 2 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Restructuring plan approved Q2 2009 following CV Therapeutics acquisition; additional $1.6M expected in H2 2010, bringing total to ~$37.0M severance/termination benefits and ~$32.5M facilities-related expenses. No employee count disclosed. Announcement date reflects quarter of plan approval; specific date not stated.
2010-06-30restructuringin_progress2009-04-012010-12-31GlobalCardiovascular R&D and SG&AUSD 70 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved Q2 2009 to realize synergies from CV Therapeutics acquisition. Total expected cost: $37.0M severance and $32.5M facilities. $1.6M additional expected in H2 2010.
2010-06-30restructuringin_progress2010-04-012010-12-31United StatesLiver Disease R&DUSD 24 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan to close Durham, NC operations and consolidate liver disease work in Foster City, CA. Total expected cost: $12.3M severance and $12.0M facilities. $22.6M additional expected in H2 2010.
2010-06-30acquisition_additioncompleted2010-06-012010-07-08United StatesResearch and DevelopmentUSD 120 (millions)subsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of CGI Pharmaceuticals, Inc. closed July 8, 2010 for up to $120M. Headcount not disclosed.
2010-03-31restructuringin_progress2009-06-30United StatesCardiovascular R&D and operationsUSD 15 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		CV Therapeutics integration plan approved Q2 2009; Q1 2010 charges of $12.6M SG&A and $2.1M R&D, primarily lease terminations. No employee count disclosed. Total expected plan cost ~$36.2M severance plus $33.3M facilities.
2010-03-31restructuringin_progress2009-04-012010-12-31GlobalCardiovascular R&D and SG&AUSD 15 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved Q2 2009 following CV Therapeutics acquisition. Q1 2010 charges: $12.6M SG&A and $2.1M R&D, primarily lease termination costs. Total expected charges: ~$36.2M employee benefits and $33.3M facilities. Employee count not disclosed.
2009-12-31acquisition_additioncompleted2009-03-122009-04-17United StatesCardiovascular (Ranexa, Lexiscan)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition closed April 15-17, 2009; consideration $1.39 billion. Headcount added through the acquisition is not disclosed.
2009-12-31restructuringin_progress2009-06-302010-12-31United StatesCardiovascular R&D and operationsUSD 52 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Approved Q2 2009 to realize CV Therapeutics synergies; 2009 charges of $26.2M in SG&A and $25.7M in R&D (severance, relocation, lease termination, facilities). Additional $20.2M expected in 2010; full program totals approximately $38.8M severance and $33.3M facilities. Employees affected not disclosed.
2009-12-31restructuringin_progress2009-06-30GlobalCardiovascular R&D and OperationsUSD 52 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Plan approved in Q2 2009 to realize synergies with CV Therapeutics acquisition. Includes consolidation of cardiovascular R&D, exit from facilities, and termination of contracts. Recorded $26.2M SG&A and $25.7M R&D expenses in 2009. Employee count not explicitly disclosed.
2009-09-30acquisition_additioncompleted2009-04-15United StatesCardiovascularbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of CV Therapeutics completed April 15, 2009; no employee headcount added disclosed.
2009-09-30restructuringin_progress2009-06-302010-12-31United StatesCardiovascular R&D and operationsUSD 62 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved Q2 2009; expected total ~$34M severance, $22M facilities, $6M relocation through 2010. No employee count disclosed.
2009-09-30restructuringin_progress2009-06-302010-12-31GlobalCardiovascular R&D and OperationsUSD 62 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q2 2009 to realize synergies with CV Therapeutics acquisition. Includes consolidation of cardiovascular R&D, facility exits, and contract terminations. Total expected costs: $34M severance, $22M facilities, $6M relocation. Majority of expenses expected by end of 2009.
2009-06-30restructuringin_progress2009-06-302010-12-31United StatesCardiovascular R&D and operationsUSD 24 (millions)restructuring_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Plan approved in Q2 2009 to realize synergies from CV Therapeutics acquisition; $12.9M in SG&A and $11.2M in R&D recorded. Expected total ~$30M severance and ~$25M facilities costs through 2010. Severance accrual of $21.6M incurred during period; no employee count disclosed.
2009-06-30acquisition_additioncompleted2009-04-152009-04-17United StatesCardiovascularbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of CV Therapeutics completed April 15, 2009; headcount added not disclosed. Approximately 1.8 million stock options converted for assumed employees.
2009-06-30restructuringin_progress2009-06-302010-12-31GlobalCardiovascular R&D and OperationsUSD 55 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Plan approved in Q2 2009 to realize synergies with CV Therapeutics. Includes consolidation of cardiovascular R&D, exit from facilities, and termination of contractual obligations. Expected total costs: $30M for severance/termination benefits and $25M for facilities-related costs. Majority of expenses expected by end of 2009.
2009-03-31acquisition_additioncompleted2009-032009-04-17United StatesCardiovascular (Ranexa, Lexiscan)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Agreement signed March 2009 to acquire CV Therapeutics for $20.00 per share (~$1.4 billion); closed 2009-04-17, after quarter end. No employee count disclosed for the acquired workforce.
2008-12-31acquisition_additioncompleted2008-05-01United StatesResearch and DevelopmentUSD 11 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		May 2008 asset purchase of cicletanine business for $10.9M expensed as purchased IPR&D; no employee counts disclosed for the transaction
2007-12-31acquisition_additioncompleted2007-09-062007-09-06IrelandManufacturingUSD 48 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Nycomed Limited, a Cork, Ireland manufacturing and tableting operation; aggregate purchase price $48.3M allocated primarily to property, plant and equipment. Headcount added not disclosed.
2007-12-31restructuringin_progress2007-12-31IrelandManufacturingUSD 3 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Transfer of certain operations from Dublin site to Cork facility triggered one-time termination benefits of approximately $3.2M recognized in Q4 2007, plus approximately $0.6M relocation and $1.0M retention benefits. Number of employees affected not disclosed.
2007-12-31restructuringcompleted2007-09-062007-12-31IrelandManufacturingUSD 3 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Termination benefits recognized in Q4 2007 related to transfer of operations from Dublin to Cork facility.
2007-12-31restructuringcompleted2005-06-012005-09-30United KingdomAdministrativeUSD 8 (millions)other
f5-10k / Qwen3.6-27B-Q8_0		Charge accrued in Q3 2005 for relocation of European HQ from Paris to London area. Majority paid in 2005/2006.
2007-06-30acquisition_additionannounced2007-08-022007-09-30IrelandManufacturing (solid dose manufacturing and EU product packaging)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Gilead Sciences Limited agreed to acquire Nycomed Limited (Cork facility) for EUR 33.9 million (~$46.5 million), expected to close in Q3 2007; no employee count disclosed. Gilead intends to transfer certain Dublin operations to the site.
2006-12-31acquisition_additioncompleted2006-10-012006-11-17United States (Westminster, Colorado)Respiratory and cardiopulmonary (R&D and commercial)USD 2,444 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Aggregate purchase price $2.44B; includes $4.0M employee-related severance under a workforce reduction plan established at acquisition and $85.5M fair value of vested assumed options. No employee headcount for Myogen disclosed.
2006-12-31acquisition_additioncompleted2006-04-122006-08-11United States (Seattle, Washington)Respiratory (cystic fibrosis pipeline)USD 416 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price includes $4.0M employee-related severance under an acquisition-related workforce reduction plan and $7.4M vested assumed options. No employee headcount for Corus disclosed.
2006-12-31acquisition_additioncompleted2006-06-062006-11-03Canada (Edmonton, Alberta)Manufacturing / API process research and scale-upUSD 133 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Purchase price includes $0.1M employee-related severance under an acquisition-related workforce reduction plan; severance fully paid by December 31, 2006. No employee headcount for Raylo disclosed.
2006-12-31restructuringcompleted2005-06-012006-12-31France to United KingdomEuropean commercial, medical and administrative headquartersUSD 8 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Multi-year program; $8.4M severance/termination charge accrued in Q3 2005 (prior fiscal year). During 2006 most accrual was paid and relocation activities were largely completed; aggregate severance, relocation and recruiting costs of approximately $14M to date. No employee count disclosed.
2006-12-31acquisition_additioncompleted2006-11-17Westminster, ColoradoCardiopulmonaryUSD 2,440 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Completed acquisition of Myogen, Inc. for aggregate purchase price of $2.44 billion.
2006-12-31acquisition_additioncompleted2006-08-11Seattle, WashingtonRespiratoryUSD 416 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Completed acquisition of Corus Pharma, Inc. for aggregate purchase price of $415.5 million.
2006-12-31acquisition_additioncompleted2006-11-03Edmonton, Alberta, CanadaManufacturingUSD 133 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Completed acquisition of Raylo Chemicals Inc. for aggregate purchase price of $133.3 million.
2006-12-31restructuringcompleted2005-06-01France to United KingdomEuropean HeadquartersUSD 8 (millions)Notes to Consolidated Financial Statements
f5-10k / Qwen3.6-27B-Q8_0		Accrued charge of $8.4 million primarily consisting of employee severance costs and termination benefits related to relocation of European headquarters from Paris to London area.
2006-09-30acquisition_additioncompleted2006-08-112006-08-11United States (Seattle, Washington)Research and Development; Selling, General and AdministrativeUSD 4 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Corus acquisition closed 2006-08-11; purchase price $414.7M includes $4.0M employee-related severance costs tied to a workforce reduction plan. No employee count disclosed. Corus results included from 2006-08-11.
2006-09-30restructuringin_progress2005-06-01France to United Kingdom (London/Cambridge area)Commercial, medical and administrative groups (European headquarters relocation)USD 2 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Relocation announced June 2005; $8.4M accrual originally booked, $6.3M incurred as of 2006-09-30, $2.1M remaining accrual. Aggregate severance, relocation and recruiting costs estimated at $10M–$13M. No employee count disclosed.
2006-09-30acquisition_additionannounced2006-10-012006-12-31United States (Westminster, Colorado)Cardiovascular therapeutics (Myogen, Inc.)USD 2,500 (millions)subsequent_events
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Definitive merger agreement signed 2006-10-01 for approximately $2.5B cash; expected to close Q4 2006. Company expects a material purchased IPR&D charge upon closing. No employee count disclosed.
2006-09-30acquisition_additioncompleted2006-11-032006-11-03CanadaCustom manufacturing of API and advanced intermediates (Raylo Chemicals Inc.)USD 136 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Subsequent-event acquisition completed 2006-11-03 for approximately €107.1M (~$136M). No employee count disclosed.
2006-09-30restructuringin_progress2005-06-01EuropeCommercial, medical and administrativeUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Relocation of European headquarters from Paris to London area. $8.4M accrued in Q3 2005 for severance and termination benefits. $6.3M incurred by Sept 30, 2006, leaving $2.1M accrual. Total expected costs $10M-$13M.
2006-09-30acquisition_additioncompleted2006-08-11Seattle, WashingtonResearch and developmentUSD 4 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Corus Pharma completed Aug 11, 2006. Purchase price included $4.0M for employee-related severance costs due to workforce reduction plan.
2006-09-30acquisition_additioncompleted2006-11-03CanadaManufacturingsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Acquisition of Raylo Chemicals Inc. completed Nov 3, 2006 for approx €107.1M ($136M). Operations encompass custom manufacturing of API.
2006-06-30restructuringin_progress2005-06France; United KingdomEuropean headquarters — commercial, medical and administrative groupsUSD 8 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Relocation of Paris-based commercial, medical and administrative groups to the London area announced June 2005; $8.4M severance and termination benefit charge accrued in Q3 2005, of which $5.7M charged against the accrual through June 30, 2006. Company expects aggregate severance, relocation and recruiting costs of $10M to $13M. Number of employees affected not disclosed.
2006-06-30restructuringin_progress2005-06-01EuropeCommercial, medical and administrativeUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Relocation of European headquarters from Paris to London area. Accrued $8.4 million in Q3 2005 for severance and termination benefits. $5.7 million charged against accrual as of June 30, 2006. Total expected costs $10-13 million.
2006-06-30otherannounced2006-03-01EuropeDistributionsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Initiated evaluation of European distribution framework with intent to terminate certain distribution agreements. Contract termination costs probable but not reasonably estimable.
2006-03-31restructuringin_progress2005-062006-06-30France / United KingdomEuropean headquarters — commercial, medical and administrative groupsUSD 8 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Relocation of European HQ from Paris to the London area; $8.4M severance accrual recorded in Q3 2005, of which ~$4.4M charged against accrual as of 2006-03-31; remaining payments expected in Q2 2006. Aggregate severance, relocation and recruiting costs estimated at $10M–$13M. Number of employees affected not disclosed.
2006-03-31restructuringin_progress2005-06-012006-06-30EuropeCommercial, Medical, AdministrativeUSD 8 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Relocation of European headquarters from Paris to London. Accrued $8.4M in Q3 2005 for severance and termination benefits. $4.4M charged against accrual as of March 31, 2006. Remaining payments expected in Q2 2006. Total aggregate costs estimated at $10M-$13M.
2006-03-31otherannounced2006-03-01EuropeDistributionsubsequent_events
f5-10q / Qwen3.6-27B-Q8_0		Initiated contact with certain European distributors regarding intent to terminate distribution relationships outside of five largest markets. Lengthy negotiations expected. Contract termination costs probable but not reasonably estimable; no amount accrued.
2005-12-31restructuringin_progress2005-062006-06-30France / United KingdomEuropean commercial, medical and administrative headquartersUSD 8 (millions)other
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Relocation of European HQ from Paris to London area; $8.4M severance accrual recorded in Q3 2005 within SG&A, ~$3.0M charged against accrual by year-end; aggregate severance, relocation and recruiting costs estimated at $10M to $13M. Number of employees affected not disclosed.
2005-12-31restructuringin_progress2005-06-012006-06-30France to United KingdomCommercial, Medical, AdministrativeUSD 8 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Relocation of European headquarters from France to UK. Accrued $8.4M in Q3 2005 for severance and termination benefits. Total aggregate costs estimated at $10M-$13M.
2005-09-30restructuringin_progress2005-062006-06-30France to United Kingdom (European headquarters relocation)Commercial, medical and administrative groupsUSD 8 (millions)other
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Charge accrued in Q3 2005 when relocation plans finalized; primarily severance and termination benefits. Aggregate severance, relocation and recruiting costs estimated at $10-13 million. Majority of payments expected over the following nine months. No employee count disclosed.
2005-09-30restructuringin_progress2005-06-012006-06-30EuropeCommercial, medical and administrativeUSD 8 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Relocation of European headquarters from Paris to London. Accrued $8.4 million for severance and termination benefits. Total expected costs $10-13 million. Majority of payments expected over next nine months.
2005-06-30otherin_progressFrance / United Kingdom (Europe)Commercial, medical and administrative groups of European headquartersother
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Announced in Q2 2005; European HQ moving from Paris to London area over three to six months. Estimated aggregate relocation, severance and recruiting costs of $10 to $13 million, expensed primarily in H2 2005. No liability recognized at June 30, 2005; number of employees affected not disclosed.
2005-06-30restructuringannounced2005-06-302005-12-31EuropeCommercial, Medical, AdministrativeUSD 12 (millions)MD&A
f5-10q / Qwen3.6-27B-Q8_0		Relocation of European headquarters from Paris to London. Aggregate costs estimated at $10-13 million for relocation, severance, and recruiting. No liability recognized as of June 30, 2005 due to inability to reasonably estimate employee acceptance.
2004-12-31restructuringcompleted2003-12San Dimas, CaliforniaResearch and DevelopmentUSD 10 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Recorded $10.2 million asset impairment charge on long-lived assets driven by decision to terminate liposomal R&D activities and discontinue DaunoXome product line.
2004-12-31acquisition_additioncompleted2003-01-23United StatesResearch and DevelopmentMD&A
f5-10k / Qwen3.6-27B-Q8_0		Acquisition of Triangle Pharmaceuticals completed in January 2003 to expand antiviral pipeline. Included employee related costs of $6.6 million.
2003-12-31acquisition_additioncompleted2003-01-232003-01-23United StatesResearch & DevelopmentUSD 6 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Triangle net assets closed 2003-01-23; a workforce reduction plan and change-of-control obligations of approximately $6.2M were recorded as liabilities at acquisition date, payable over about two years ($3.6M remaining at 2003-12-31). Headcount added not disclosed.
2003-12-31plant_closurecompleted2003-12-312003-12-31United StatesSan Dimas, California — liposomal R&D and DaunoXome product lineUSD 10 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		December 2003 decision to terminate liposomal R&D activities in San Dimas and discontinue DaunoXome; $10.2M non-cash impairment of long-lived assets. Employee count affected not disclosed.
2003-12-31restructuringcompleted2003-12San Dimas, CaliforniaLiposomal research and developmentUSD 10 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		In December 2003, the company decided to terminate liposomal R&D activities in San Dimas and discontinue the DaunoXome product line, resulting in a $10.2 million asset impairment charge. Specific headcount affected is not disclosed.
2003-12-31acquisition_additioncompleted2003-01-23United StatesResearch and DevelopmentUSD 525 (millions)business_combinations_footnote
f5-10k / Qwen3.6-27B-Q8_0		Acquired net assets of Triangle Pharmaceuticals in January 2003. Included $6.6 million in employee-related costs and a workforce reduction plan with $6.2 million in termination costs recorded as liability. Specific headcount added or reduced is not disclosed.
2003-09-30acquisition_additioncompleted2003-01-23United StatesResearch and DevelopmentUSD 489 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of all outstanding Triangle stock completed 2003-01-23; purchase price $525.2M including $41.3M fair value of assumed stock options. No employee headcount added is disclosed; a $4.6M assembled-workforce asset is amortized over 3 years. Charge shown is the in-process R&D expense recorded.
2003-09-30restructuringin_progress2003-01-232005-01-23United StatesOther (change of control and workforce reduction obligations)USD 6 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Workforce reduction plan and change-of-control obligations established at the Triangle acquisition date; $6.2M recorded as liability at acquisition, $4.1M remaining at 2003-09-30, payable over approximately 2 years. Number of employees affected is not disclosed.
2003-09-30restructuringin_progress2003-01-232005-01-23USD 6 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Workforce reduction plan established as part of Triangle acquisition; $6.2M recorded for termination costs and change of control obligations to be paid over approx. 2 years.
2003-06-30acquisition_additioncompleted2003-01-232003-01-23United StatesResearch and Developmentbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Triangle Pharmaceuticals completed January 23, 2003; purchase price $525.2 million including $41.3 million fair value of assumed stock options. No employee headcount added disclosed; purchase price allocation includes $4.6 million for assembled workforce amortized over 3 years.
2003-06-30restructuringin_progress2003-01-232005-01-23United StatesResearch and DevelopmentUSD 6 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Workforce reduction plan and change-of-control obligations established at acquisition; $6.2 million recorded as liability at acquisition date, payable over approximately 2 years; $4.9 million remained as liability at June 30, 2003. No employee count disclosed.
2003-06-30restructuringin_progress2003-01-232005-01-23USD 6 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Workforce reduction plan established as part of Triangle acquisition; $6.2M recorded for termination costs and change of control obligations to be paid over approx. 2 years.
2003-03-31acquisition_additioncompleted2003-01-232003-01-23United States (Durham, North Carolina)Research and Development; Selling, General and AdministrativeUSD 41 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Headcount not quantified. Purchase price includes $41.3M fair value of assumed stock options; Triangle operations added $8.5M R&D and $1.2M SG&A expenses since acquisition date.
2003-03-31restructuringin_progress2003-01-232005-01-23United StatesTriangle Pharmaceuticals (acquired entity)USD 7 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Workforce reduction plan established at acquisition; $6.2M severance liability recorded at acquisition date, $5.5M remaining at 2003-03-31, payable over approximately 2 years. Number of employees affected not disclosed.
2003-03-31restructuringin_progress2003-01-232005-01-23USD 7 (millions)business_combinations_footnote
f5-10q / Qwen3.6-27B-Q8_0		Workforce reduction plan established as part of Triangle acquisition. $6.2M recorded as severance liability at acquisition, payable over approx. 2 years. $5.5M remained as liability at March 31, 2003. Employee count not disclosed.
2002-12-31acquisition_additioncompleted2002-12-102003-01-23United States (Durham, North Carolina)Research and Development (antiviral drug candidates)USD 525 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Acquisition of Triangle Pharmaceuticals completed 2003-01-23; aggregate preliminary purchase price of $525.0 million, a substantial portion expected to be recorded as in-process R&D expense. Headcount added not disclosed. Tender offer announced via Form 8-K filed 2002-12-10 at $6.00 per share; a $50.0 million 7.50% convertible note was extended to Triangle in December 2002 and eliminated on consolidation at closing.
2002-12-31acquisition_additioncompleted2002-12-102003-01-23United States (Durham, North Carolina)Research and development (antiviral drug candidates)USD 525 (millions)subsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tender offer for Triangle Pharmaceuticals announced December 2002; acquisition closed 2003-01-23 for a preliminary aggregate purchase price of $525.0 million, a substantial portion expected to be expensed as in-process R&D. No employee headcount added is disclosed. Announcement date taken from the Form 8-K regarding the $6.00/share tender offer.
2002-12-31acquisition_additioncompleted2002-12-102003-01-23United StatesResearch and Developmentsubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Tender offer for Triangle Pharmaceuticals announced via Form 8-K dated 2002-12-10 at $6.00 per share; acquisition of all outstanding stock closed 2003-01-23 for an aggregate preliminary purchase price of $525.0 million, which included estimated direct transaction costs and employee termination costs (amounts not separately quantified). Headcount added through the acquisition is not disclosed. A $50.0 million 7.50% convertible note extended to Triangle in December 2002 was eliminated in consolidation upon closing. Gilead expects to record a substantial portion of the purchase price as in-process R&D expense in Q1 2003.
2001-12-31divestiture_reductioncompleted2001-112001-12-21United States (Boulder, Colorado)Oncology — clinical research and drug development operationsrestructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Sale of oncology pipeline, related IP and Boulder, CO operations (personnel, infrastructure, facilities) to OSI Pharmaceuticals, completed 2001-12-21; headcount transferred not disclosed. Related $2.8M charge for accelerated options for ~78,000 shares.
2001-12-31restructuringcompleted301999-12-311999-12-31Boulder, ColoradoResearch and DevelopmentMD&A
f5-10k / Qwen3.6-27B-Q8_0		Reduction of R&D workforce in Boulder by 30 employees upon completing the merger with NeXstar in 1999. Mentioned in 2001 filing for context on expense trends.
2001-12-31divestiture_reductioncompleted2001-11-262001-12-21Boulder, ColoradoOncologyMD&A
f5-10k / Qwen3.6-27B-Q8_0		Sale of oncology assets to OSI Pharmaceuticals included transfer of clinical research and drug development personnel, infrastructure and facilities in Boulder. Specific headcount not disclosed.
2000-12-31restructuringcompleted701999-07-292000-12-31United StatesAll functionsUSD 5 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Merger-related employee severance costs of $5.3 million relating to the termination of 70 employees, majority from Boulder, CO facility. All terminated by Dec 31, 1999; substantially all costs paid by Dec 31, 2000.
2000-12-31restructuringcompleted301999-07-291999-12-31United StatesResearch and DevelopmentMD&A
f5-10k / Qwen3.6-27B-Q8_0		Reduction of R&D workforce in Boulder by 30 employees upon completion of the merger with NeXstar in 1999.
1999-12-31restructuringcompleted701999-07-291999-12-31United StatesPrimarily Boulder, Colorado facilityUSD 5 (millions)restructuring_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Merger-related employee severance; all accrued employees terminated by Dec 31, 1999; $2.5M accrual balance remaining at year-end, expected paid by September 2000. Includes 30 R&D employees in Boulder reduced upon merger completion.
1999-12-31acquisition_additioncompleted1999-07-291999-07-29United StatesAll functionsUSD 18 (millions)business_combinations_footnote
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Stock-for-stock merger with NeXstar Pharmaceuticals completed July 29, 1999; 11.2 million Gilead shares issued. Total merger-related expenses of $18.3M including $12.2M transaction costs, $5.3M severance, $0.5M asset write-down. NeXstar headcount added not explicitly disclosed.
1999-12-31restructuringcompleted701999-07-291999-12-31United StatesAll functionsUSD 5 (millions)MD&A
f5-10k / Qwen3.6-27B-Q8_0		Merger-related employee severance costs for 70 employees, majority from Boulder, CO facility. All terminated by Dec 31, 1999.
1999-12-31restructuringcompleted301999-07-291999-12-31United StatesResearch and DevelopmentMD&A
f5-10k / Qwen3.6-27B-Q8_0		Reduction of R&D workforce in Boulder by 30 employees upon completing merger with NeXstar.
1999-09-30acquisition_additioncompleted1999-07-291999-07-29USD 18 (millions)business_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger closed 1999-07-29; no headcount added disclosed. Merger-related costs of $18.2M include $5.8M employee severance ($2.0M utilized, $3.8M accrual at quarter-end); no employee counts given.
1999-09-30restructuringin_progress1999-02-28USD 6 (millions)restructuring_footnote
f5-10q / Qwen3.6-27B-Q8_0		Merger-related employee severance costs charged to expense. Total merger-related costs were $18.2 million, including transaction costs and asset write-downs. Employee count affected is not disclosed.
1999-06-30acquisition_additioncompleted1999-02-281999-07-29United Statesbusiness_combinations_footnote
f5-10q / MiMo-V2.6-Flash-fp8-HTML		Merger closed 1999-07-29 (subsequent to quarter end); Gilead issued ~11,212,730 shares. Filing does not disclose NeXstar headcount added or any workforce changes associated with the merger.
1998-12-31acquisition_additionannounced1999-03-011999-06-30United States (Boulder, CO; San Dimas, CA) and worldwideAll functionssubsequent_events
f5-10k / MiMo-V2.6-Flash-fp8-HTML		Definitive merger agreement to acquire NeXstar Pharmaceuticals announced 1999-03-01; stock-for-stock, expected completion mid-1999. No employee count disclosed for NeXstar.